A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | MicrobiomeTrials
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-10Est. Completion: 2026-09
Enrollment target: 49 participants
Locations
The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing Municipality, China
Peking University Third Hospital /ID# 228138, Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital /ID# 231890, Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center /ID# 228033, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital /ID# 228028, Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 227916, Guangzhou, Guangdong, China
Henan Cancer Hospital /ID# 228772, Zhengzhou, Henan, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221, Wuhan, Hubei, China
Hunan Cancer Hospital /ID# 231859, Changsha, Hunan, China
The First Affiliated Hospital of Soochow University /ID# 228024, Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College /ID# 228774, Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University /ID# 228771, Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital /ID# 231944, Nanchang, Jiangxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in